Literature DB >> 15799759

Complement activation in acute coronary syndromes.

Kenan Iltumur1, Aziz Karabulut, Gülten Toprak, Nizamettin Toprak.   

Abstract

The complement system is part of the host defence response. However, considerable evidence suggests that complement plays an important role in the pathophysiology of ischemic heart disease. The aim of this study was to evaluate complement activation in patients with all forms of acute coronary syndromes (ACS) and to examine the relationship between the degree of complement activation and myocardial injury. The study population included 152 subjects (26 females): 82 with ACS (35 acute myocardial infarction (AMI), 22 non-Q wave MI (NQMI), 25 unstable angina (UAP)) (Group A), 35 stable angina (SA) (Group B), and 35 healty control subjects (Group C). Complement 3 (C3), Complement 4 (C4), C-reactive protein (CRP), troponin I (TnI) as well as creatine kinase MB (CK-MB) were evaluated. Patients' blood samples were taken on admission (day 1) and after 2, 3 and 7 days in group A. However, only one measurement was performed in the groups B and C. Plasma C3 and C4 peak levels were significantly higher in patients with AMI (141+/-29 and 35+/-11 mg/dl) and NQMI (136+/-13 and 35+/-7 mg/dl) than in patients with SA (128+/-14 and 27+/-10 mg/dl) and the control subjects (114+/-22 and 22+/-7 mg/dl) (p<0.03). Also, C3 and C4 serum levels in patients with SA and UAP (126+/-16 and 31+/-7 mg/dl) were significantly higher than those in control subjects (p<0.01, p<0.03, respectively). At 1-week follow-up, there were no significant differences between the plasma levels of C3 and C4 in patients with UAP (p>0.05). However, plasma levels of C3 and C4 were significantly different between days in patients with AMI and NQMI (p<0.0001). Plasma C3 and C4 levels in ACS showed a relationship with peak CK-MB and Tn I levels (p<0.01). Plasma CRP level in ACS showed positive correlation with C3 (p<0.01) and C4 (p<0.001). In this study, we determined that plasma C3 and C4 levels were elevated in ACS and SA. Although C3 and C4 were higher in ACS and SA, the systemic levels of inflammatory markers in patients with SA and UAP were lower than those found in the AMI and NQMI groups. The relationship between C3, C4 levels and ACS further suggests that the complement activation is related to necrosis within the myocardium.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15799759     DOI: 10.1111/j.1600-0463.2005.apm1130303.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  12 in total

1.  Serum complements and heart fatty acid binding protein in Bangladeshi patients with acute myocardial infarction.

Authors:  Nayareen Akhtar; Abu Taher; Rezwanur Rahman; Ashesh Kumar Chowdhury
Journal:  Heart Asia       Date:  2012-09-26

2.  Acute and long-term effect of percutaneous coronary intervention on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable angina.

Authors:  Gregor Leibundgut; Jun-Hee Lee; Bradley H Strauss; Amit Segev; Sotirios Tsimikas
Journal:  J Thromb Thrombolysis       Date:  2016-05       Impact factor: 2.300

Review 3.  The role of complement activation in atherogenesis: the first 40 years.

Authors:  Sonia I Vlaicu; Alexandru Tatomir; Violeta Rus; Armugam P Mekala; Petru A Mircea; Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

4.  Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1.

Authors:  Osama A Hamad; Per H Nilsson; Diana Wouters; John D Lambris; Kristina N Ekdahl; Bo Nilsson
Journal:  J Immunol       Date:  2010-02-05       Impact factor: 5.422

5.  Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets.

Authors:  O A Hamad; K N Ekdahl; P H Nilsson; J Andersson; P Magotti; J D Lambris; B Nilsson
Journal:  J Thromb Haemost       Date:  2008-05-22       Impact factor: 5.824

6.  High serum C1q-binding adiponectin levels in male patients with acute coronary syndrome.

Authors:  Ken Kishida; Yasuhiko Nakagawa; Hironori Kobayashi; Toru Mazaki; Hiroyoshi Yokoi; Koji Yanagi; Tohru Funahashi; Iichiro Shimomura
Journal:  Cardiovasc Diabetol       Date:  2014-01-09       Impact factor: 9.951

7.  Immune Cell Repertoire and Their Mediators in Patients with Acute Myocardial Infarction or Stable Angina Pectoris.

Authors:  Wenwen Yan; Yanli Song; Lin Zhou; Jinfa Jiang; Fang Yang; Qianglin Duan; Lin Che; Yuqin Shen; Haoming Song; Lemin Wang
Journal:  Int J Med Sci       Date:  2017-02-08       Impact factor: 3.738

8.  Complement Inhibition Targeted to Injury Specific Neoepitopes Attenuates Atherogenesis in Mice.

Authors:  Shen Dai; Fengming Liu; Mi Ren; Zhongnan Qin; Namita Rout; Xiao-Feng Yang; Hong Wang; Stephen Tomlinson; Xuebin Qin
Journal:  Front Cardiovasc Med       Date:  2021-09-28

9.  Anticomplement therapy.

Authors:  Prathit A Kulkarni; Vahid Afshar-Kharghan
Journal:  Biologics       Date:  2008-12

10.  Complement sC5b-9 and CH50 increase the risk of cancer-related mortality in patients with non-small cell lung cancer.

Authors:  Jing Li; Zhijun Cao; Lijie Mi; Zhihua Xu; Xiangmei Wu
Journal:  J Cancer       Date:  2020-10-18       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.